- Home
- NUKK vs IMUX Comparison
NUKK vs IMUX Comparison
Compare NUKK & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUKK
- IMUX
- Stock Information
- Founded
- NUKK 2013
- IMUX 2016
- Country
- NUKK United States
- IMUX United States
- Employees
- NUKK N/A
- IMUX N/A
- Industry
- NUKK Blank Checks
- IMUX Biotechnology: Pharmaceutical Preparations
- Sector
- NUKK Finance
- IMUX Health Care
- Exchange
- NUKK Nasdaq
- IMUX Nasdaq
- Market Cap
- NUKK 100.0M
- IMUX 92.2M
- IPO Year
- NUKK N/A
- IMUX N/A
- Fundamental
- Price
- NUKK $7.12
- IMUX $0.82
- Analyst Decision
- NUKK
- IMUX Strong Buy
- Analyst Count
- NUKK 0
- IMUX 5
- Target Price
- NUKK N/A
- IMUX $7.00
- AVG Volume (30 Days)
- NUKK 2.6M
- IMUX 1.6M
- Earning Date
- NUKK 11-14-2025
- IMUX 11-06-2025
- Dividend Yield
- NUKK N/A
- IMUX N/A
- EPS Growth
- NUKK N/A
- IMUX N/A
- EPS
- NUKK N/A
- IMUX N/A
- Revenue
- NUKK N/A
- IMUX N/A
- Revenue This Year
- NUKK N/A
- IMUX N/A
- Revenue Next Year
- NUKK N/A
- IMUX N/A
- P/E Ratio
- NUKK N/A
- IMUX N/A
- Revenue Growth
- NUKK N/A
- IMUX N/A
- 52 Week Low
- NUKK $1.30
- IMUX $0.56
- 52 Week High
- NUKK $78.32
- IMUX $1.42
- Technical
- Relative Strength Index (RSI)
- NUKK 45.16
- IMUX 48.29
- Support Level
- NUKK $6.71
- IMUX $0.78
- Resistance Level
- NUKK $8.70
- IMUX $0.87
- Average True Range (ATR)
- NUKK 1.81
- IMUX 0.05
- MACD
- NUKK -0.46
- IMUX -0.00
- Stochastic Oscillator
- NUKK 5.41
- IMUX 45.35
About NUKK Nukkleus Inc.
Nukkleus Inc is a financial technology company that is focused on providing software and technology solutions. The company's operating segment includes General support services and Financial services. General support services include providing software, technology, customer sales and marketing, and risk management technology hardware and software solutions package under a GSA to a related party. Financial services include providing payment services from one fiat currency to another or to digital assets. It generates maximum revenue from the General support services segment. Geographically operates in USA, UK and Malta, with majority of revenue from United Kingdom (UK).
About IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.